MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Cash Flow Overview

Change in Cash
$282,961K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Issuance of stock in connection ...
    • Paramora warrant obligation
    • Stock-based compensation
    • Others
Negative Cash Flow Breakdown
    • Net loss
    • Issuance costs in connection wit...
    • Related party accounts payable a...
    • Others

Cash Flow
2026-06-30
Net loss
-58,957
Depreciation of equipment
11
Stock-based compensation
9,278
Amortization of right of use lease asset
68
Prepaid expenses and other current assets
274
Other assets, noncurrent
23
Accounts payable
3,038
Accrued expenses and other current liabilities
6,494
Operating lease liabilities
-67
Paramora warrant obligation
9,527
Related party accounts payable and other current liabilities
-11,559
Other liabilities, noncurrent
-1
Net cash used in operating activities
-42,465
Issuance of stock in connection with offerings
346,217
Issuance costs in connection with offerings
21,441
Proceeds from exercise of stock options
650
Net cash provided by financing activities
325,426
Net increase (decrease) in cash and cash equivalents
282,961
Effect of exchange rate changes on cash and cash equivalents
-70
Cash and cash equivalents, beginning of year
257,624
Cash and cash equivalents, end of year
540,515
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Issuance of stock inconnection with offerings$346,217K Proceeds from exercise ofstock options$650K Net cash provided byfinancing activities$325,426K Canceled cashflow$21,441K Net increase(decrease) in cash and cash...$282,961K Canceled cashflow$42,465K Issuance costs inconnection with offerings$21,441K Paramora warrantobligation$9,527K Stock-based compensation$9,278K Accrued expenses andother current...$6,494K Accounts payable$3,038K Amortization of right of uselease asset$68K Depreciation of equipment$11K Net cash used inoperating activities-$42,465K Canceled cashflow$28,416K Net loss-$58,957K Related party accountspayable and other...-$11,559K Prepaid expenses andother current assets$274K Operating leaseliabilities-$67K Other assets,noncurrent$23K Other liabilities,noncurrent-$1K

Damora Therapeutics, Inc. (DMRA)

Damora Therapeutics, Inc. (DMRA)